Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories, Inc.

Key Points
Non-GAAP earnings per share of $2.61 in Q2 2025 beat analyst estimates by 50.9%, and Non-GAAP revenue of $651.6 million in Q2 2025 exceeded forecasts by 5.9%.
GAAP revenue in the Life Science segment returned to growth, increasing 4.9% in Q2 2025, while Net sales in the Clinical Diagnostics segment remained essentially flat year-over-year in Q2 2025, with persistent pressure in China.
Gross and operating margins declined year over year in Q2 2025, with tariff challenges contributing to margin compression.
Bio-Rad Laboratories (NYSE:BIO), a global leader in life science research and clinical diagnostics, posted its second quarter 2025 financial results on July 31, 2025. The most important news was a clear earnings and revenue beat: Adjusted earnings per share (non-GAAP) were $2.61 in Q2 2025, well above the $1.73 non-GAAP analyst consensus for Q2 2025. Non-GAAP revenue reached $651.6 million in Q2 2025 compared to the $615.2 million non-GAAP revenue expectation. Sales saw slight growth compared to the same period in 2024, with total net sales increasing by 2.1% in Q2 2025 versus Q2 2024, GAAP and non-GAAP gross margins declined in Q2 2025 compared to Q2 2024, and GAAP operating margin also declined, underlining persistent challenges despite headline results. Overall, the quarter showed strong top-line performance, steady innovation, and ongoing margin pressure amid ongoing industry and geopolitical headwinds.
Metric
Q2 2025
Q2 2025 Estimate
Q2 2024
Y/Y Change
EPS (Non-GAAP)
$2.61
$1.73
$3.11
(16.1%)
Revenue
$651.6 million
$615.2 million
$638.5 million
2.1%
Revenue – Clinical Diagnostics segment
$388.8 million
N/A
N/A
Non-GAAP Operating Margin
13.6%
16.7%
(3.1 pp)
Free Cash Flow (Non-GAAP)
$70.8 million
$55.4 million
N/A
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Company overview and strategic focus
Bio-Rad Laboratories specializes in the development and manufacturing of products for life science research and clinical diagnostics. Its tools and systems help scientists and healthcare professionals to conduct biological research and perform diagnostic testing for diseases and medical conditions.
The company’s recent focus has revolved around innovation through research and development, expansion of its product portfolio, and targeted strategic acquisitions. Staying ahead of regulatory changes while maintaining strong global distribution and investing in technology and manufacturing are all key to its ongoing success. Execution in these areas, together with effective cost control and adaptation to market trends, is crucial for Bio-Rad's performance in both its Life Science and Clinical Diagnostics businesses.
Quarterly performance and notable developments
In Q2 2025, Bio-Rad delivered results that surpassed Wall Street’s expectations on both revenue and adjusted (non-GAAP) earnings per share. Revenue grew 2.1% year-over-year on a GAAP basis in Q2 2025, Non-GAAP earnings per share declined from $3.11 in the prior year to $2.61 in Q2 2025 due to margin pressures. This divergence highlights that top-line gains have not fully filtered down to profitability, a point supported by the contraction in non-GAAP operating margin from 16.7% to 13.6% in Q2 2025 compared to Q2 2024.
This segment includes instruments and consumables for laboratory research, such as digital Polymerase Chain Reaction (PCR) systems. Life Science revenue rose 4.9% in Q2 2025, led by higher demand for process chromatography products, which are used in the purification of biological molecules, and food safety product sales. However, core instrument demand remained subdued, especially in the U.S, reflecting lower government and academic funding.
The Clinical Diagnostics segment, which supplies medical testing equipment and consumables to hospitals and laboratories, saw revenue remain essentially flat in Q2 2025, with no material increase reported. Diagnostics performance was held back by ongoing reimbursement cuts for diabetes testing in China. These declines were partly offset by growth in demand for quality control and immunology diagnostics products in other global markets. Management explained, “Clinical Diagnostics segment net sales for Q2 2025 were $388.8 million, essentially flat compared to the same period in 2024. On a currency-neutral basis, net sales decreased 0.7 percent.”
Gross margin and operating margin both decreased in Q2 2025, with the company attributing this to ongoing tariffs and restructuring expenses. Tariffs between the U.S. and China alone now account for up to 130 basis points (or about $30 million) in non-GAAP operating margin impact for FY2025. Bio-Rad has responded by adding surcharges for certain customers and exploring new manufacturing strategies. Despite these challenges, reaching $70.8 million in free cash flow in Q2 2025. The period also saw the closing of the Stilla Technologies acquisition, expanding Bio-Rad's digital PCR portfolio with products like the QX Continuum system and the QX700 series -- tools supporting detection and quantification of genetic material.
Strategic investment remained active. The company's stake in Sartorius AG, a German bioprocessing and laboratory equipment company, swung sharply in value, driving a one-off profit on a GAAP basis in Q2 2025 after last year's large loss. Share repurchases also accelerated, with $242.1 million spent in the first half of 2025. Management reiterated an active appetite for pursuing larger acquisitions if attractive opportunities arise. Bio-Rad does not currently pay a dividend.
Looking ahead: Guidance and watch points
Management raised its non-GAAP outlook for FY2025. It now expects non-GAAP, currency-neutral revenue growth of around 0% to 1% for FY2025, up from prior forecasts. Non-GAAP operating margin guidance has also been increased, with a new range of 12.0% to 13.0% for FY2025, compared to the earlier 10.0% to 12.0%.
Key areas for investors to watch in the coming quarters include the trend in gross and operating margins, given ongoing pressure from tariffs, product mix, and inflation; further changes in China, where both Clinical Diagnostics and Life Science segments face uncertainty; and developments in U.S. academic funding impacting laboratory instrument sales. The success of integrating the Stilla Technologies acquisition should also be monitored, as digital PCR platforms are a growing focus for both research and applied markets. Bio-Rad does not currently pay a dividend.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,036%* — a market-crushing outperformance compared to 181% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of July 29, 2025
JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Bio-Rad (BIO) Q2 EPS Jumps 51%

In trading on Friday, shares of Bio-Rad Laboratories Inc (Symbol: BIO) crossed above their 200 day moving average of $286.23, changing hands as high as $290.15 per share. Bio-Rad Laboratories Inc shares are currently trading up about 17.8% on the day. The chart below shows the one year performance of BIO shares, versus its 200 day moving average:
Looking at the chart above, BIO's low point in its 52 week range is $211.43 per share, with $387.99 as the 52 week high point — that compares with a last trade of $287.01.
Free Report: Top 8%+ Dividends (paid monthly)
Click here to find out which 9 other stocks recently crossed above their 200 day moving average »
ASST YTD Return
ETFs Holding NOC
ZURA Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

BIO Crosses Above Key Moving Average Level

Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with the QX700 series of ddPCR platforms, which were added through its recently completed acquisition of digital PCR developer Stilla Technologies.
Combined with Bio-Rad’s existing line of QX200 and QX600 ddPCR systems, the expanded product portfolio — now including more than 400,000 assays — offers the most comprehensive line of digital PCR products for life science research and diagnostic applications.
BIO Stock’s Likely Trend Following the News
Since the July 7 announcement, Bio-Rad shares have risen 4%, closing at $256.97 on Friday. The latest development is expected to strengthen the company’s Life Science segment by complementing the existing QX ddPCR portfolio and offering customers unparalleled workflow simplicity and throughput capabilities across the full spectrum of digital PCR applications, including oncology, infectious disease and genetic research. Accordingly, we expect the news to positively influence the market sentiment surrounding BIO stock.
Bio-Rad has a market capitalization of $6.99 billion. The company’s earnings yield of 3.6% favorably compares to the industry’s 3.6% yield. In the trailing four quarters, it has delivered an earnings beat of 37.4%, on average.
Significance of Bio-Rad’s New Launches
According to a key representative of Bio-Rad’s Life Science Group, the expanded portfolio of instruments, reagents, software and services enhances Bio-Rad’s presence in the genomics research and applied science markets, solidifying its leadership in droplet digital PCR solutions. The new end-to-end solutions feature industry-leading absolute quantification, high precision and advanced multiplexing capabilities, combined with streamlined and simplified workflows.
Image Source: Zacks Investment Research
The QX Continuum ddPCR system is designed for translational research applications. It features a qPCR-like workflow that offers simplicity, performance and flexibility in an all-in-one configuration with four-color multiplexing and up to eight discrete thermal profiles per plate. Meanwhile, the QX700 series consists of three new ddPCR instruments designed for academic research, environmental testing, cell and gene therapy and biopharma quality control workflows. The systems enable seven-color multiplexing, the capacity to process more than 700 samples per day with minimal input volume, continuous loading capability and easy-to-use software for streamlined data interpretation.
BIO’s Favorable Industry Prospects
Per a research report, the global digital PCR market was valued at $706.7 million in 2024 and is expected to witness a compound annual growth rate of 23.1% by 2032. The growing prevalence of infectious diseases, cancer and genetic disorders, the introduction of products, increasing acquisitions and the rising adoption of technology by laboratories are some of the key factors expected to drive market growth during the forecast period.
Digital PCR Business Backs Bio-Rad’s Growth
The company is consistently developing its foothold in the rapidly growing digital PCR space to address additional opportunities in the PCR market. Bio-Rad’s QX600 ddPCR platform is currently robust and continues to grow. In the first quarter of 2025, it introduced key assay expansions, including enhancements to the Vericheck assays for cell and gene therapy, showing a strong correlation between circulating tumor DNA and treatment outcomes in lung cancer. Momentum was bolstered by robust reagent and consumables growth.
In 2024, several advancements were made to further expand the ddPCR platform into life science research and clinical diagnostics, including investing in Geneoscopy to support the launch of their FDA-approved, non-invasive colorectal cancer screening test powered by the ddPCR platform.
BIO Stock Price Performance
In the past six months, BIO shares have declined 24.8% against the industry’s 3.1% growth.
Bio-Rad’s Zacks Rank and Key Picks
Bio-Rad currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Boston Scientific BSX and Cencora COR. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy), Boston Scientific and Cencora each carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have remained constant at $2.04 in the past 30 days. Shares of the company have rallied 75% in the past year compared with the industry’s 10.8% growth. Its earnings yield of 7.5% compares comfortably with the industry’s 1% yield. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%.
Estimates for Boston Scientific’s 2025 earnings per share have remained constant at $2.91 in the past 90 days. Shares of the company have surged 32.3% in the past year compared with the industry’s growth of 10.8%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. In the last reported quarter, it delivered an earnings surprise of 11.9%.
Cencora shares have rallied 32.8% in the past year. Estimates for the company’s fiscal 2025 earnings per share have increased 0.4% to $15.81 in the past 30 days. COR’s earnings beat estimates in each of the trailing four quarters, the average surprise being 6%. In the last reported quarter, it posted an earnings surprise of 8.3%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms

Hologic HOLX, a women’s health-focused company, delivered a non-GAAP gross margin of 61.1% in the second quarter of fiscal 2025, up 40 basis points (bps) from the year-ago period. This was fueled by strong diagnostic sales and contributions from two recent high-margin additions — Endomagnetics and Gynesonics. While these acquisitions raised operating expenses by 1.7%, excluding them, costs were down 4.6% year over year, reflecting disciplined cost management despite a 0.5% dip in revenues at constant currency. Despite these integrations, Hologic posted a 30% operating margin in the quarter, which remains among the strongest in its peer group and also increased 60 bps sequentially.
Amid ongoing macroeconomic volatility, Hologic has taken a cautious stance on its full-year outlook. Tariffs tied to its manufacturing operations in China and Costa Rica are expected to add $20 million-$25 million to the quarterly cost of goods sold. The company also lowered its China revenue forecast by roughly $20 million to just $50 million, reducing exposure to future geopolitical risks. Following the end of USAID funding, Hologic removed its $50 million HIV testing business from Molecular Diagnostics projections. Still, the Diagnostics segment is expected to lead the overall growth for the year, rising in the mid-single digits.
Surgical is expected to grow in the high-single digits, supported by Gynesonics, International sales momentum and the strong uptake of the new Fluent Pro Fluid Management System. Further, an accelerated recovery in Skeletal product supply is also expected to boost performance. Together, these factors support Hologic’s ability to deliver gross margins in the low 60s for the full year, even as the P&L impact of the tariffs intensifies. The operating margin is also forecasted to remain healthy in the low 30s.
Scenario for Hologic’s Peers
GE Healthcare GEHC posted an 80 bps year-over-year adjusted gross margin improvement in the first quarter of 2025 due to volume growth and new, higher-margin products. GEHC’s adjusted EBIT margin of 15% improved 30 bps, led by ongoing productivity initiatives. For the full year, GE Healthcare now expects 14.2%-14.4% in the adjusted EBIT margin for the full year, with approximately $475 million of additional tariff-related costs since its February guidance.
Bio-Rad BIO, operating in the molecular diagnostics space, delivered a non-GAAP gross margin of 53.8%, down 0.7% year over year. Meanwhile, BIO’s non-GAAP operating margin increased 11.3% year over year to 10.8%, which also topped the consensus. Bio-Rad expects a net tariff headwind of 130 bps to its operating margin for 2025, mainly from shipping U.S.-manufactured products to China.
HOLX’s Price Performance, Valuation and Estimates
In the past six months, Hologic shares have dropped 10.4% compared with the industry’s decline of 13.8%.
Image Source: Zacks Investment Research
From a valuation standpoint, HOLX trades at a forward 12-month price-to-sales (P/S) of 3.42X, well above the sector. It carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Hologic’s fiscal 2025 earnings implies a 2.9% improvement year over year.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?

First Pacific Advisors, LP has added 214,705 shares of $BIO to their portfolio, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 03-31-2025 report period. You can see the fund's full portfolio on Quiver Quantitative, and also track the largest institutional owners of $BIO.
BIO-RAD LABORATORIES Hedge Fund Activity
We have seen 197 institutional investors add shares of BIO-RAD LABORATORIES stock to their portfolio, and 230 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
WEALTHFRONT ADVISERS LLC removed 1,043,153 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $254,070,344
VAN ECK ASSOCIATES CORP removed 580,281 shares (-44.5%) from their portfolio in Q4 2024, for an estimated $190,628,111
BANK OF AMERICA CORP /DE/ added 374,269 shares (+705.9%) to their portfolio in Q4 2024, for an estimated $122,951,109
SELECT EQUITY GROUP, L.P. removed 247,794 shares (-35.0%) from their portfolio in Q4 2024, for an estimated $81,402,806
FIRST PACIFIC ADVISORS, LP added 214,705 shares (+136.0%) to their portfolio in Q1 2025, for an estimated $52,293,549
MILLENNIUM MANAGEMENT LLC removed 204,723 shares (-35.1%) from their portfolio in Q4 2024, for an estimated $67,253,552
ARIEL INVESTMENTS, LLC added 181,829 shares (+48.0%) to their portfolio in Q4 2024, for an estimated $59,732,644
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIO-RAD LABORATORIES Government Contracts
We have seen $5,231,647 of award payments to $BIO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
DIAGNOSTIC TESTING: $717,635
EVOLIS ANALYZER LEASE AND SERVICE: $349,878
LYPHOCHEK WHOLE BLOOD METALS CONTROL - QUALITY CONTROL REAGENTS: $279,038
REAGENTS USED IN BIO-RAD LAB, CHEMISTRY SECTION FOR THE PATHOLOGY DEPARTMENT.: $275,585
CONSUMABLES: $259,470
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
BIO-RAD LABORATORIES Analyst Ratings
Wall Street analysts have issued reports on $BIO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
Citigroup issued a "Buy" rating on 05/02/2025
To track analyst ratings and price targets for BIO-RAD LABORATORIES, check out Quiver Quantitative's $BIO forecast page.
Note that there may be inaccuracies in these estimates due to filing errors by the funds, parsing errors by us, or other anomalies.
Check out Quiver Quantitative's $BIO ticker page for more data.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Fund Update: First Pacific Advisors, LP added 214,705 shares of BIO-RAD LABORATORIES ($BIO) to their portfolio

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco MSCI USA ETF (Symbol: PBUS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $65.99 per unit.
With PBUS trading at a recent price near $56.83 per unit, that means that analysts see 16.13% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of PBUS's underlying holdings with notable upside to their analyst target prices are DraftKings Inc (Symbol: DKNG), Westlake Corp (Symbol: WLK), and Bio-Rad Laboratories Inc (Symbol: BIO). Although DKNG has traded at a recent price of $34.25/share, the average analyst target is 61.26% higher at $55.23/share. Similarly, WLK has 51.85% upside from the recent share price of $79.85 if the average analyst target price of $121.25/share is reached, and analysts on average are expecting BIO to reach a target price of $350.40/share, which is 48.26% above the recent price of $236.34. Below is a twelve month price history chart comparing the stock performance of DKNG, WLK, and BIO:
Below is a summary table of the current analyst target prices discussed above:
Name
Symbol
Recent Price
Avg. Analyst 12-Mo. Target
% Upside to Target
Invesco MSCI USA ETF
PBUS
$56.83
$65.99
16.13%
DraftKings Inc
DKNG
$34.25
$55.23
61.26%
Westlake Corp
WLK
$79.85
$121.25
51.85%
Bio-Rad Laboratories Inc
BIO
$236.34
$350.40
48.26%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
Also see:
Joel Greenblatt Stock Picks
IQV Options Chain
ETFs Holding CLCD
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Analysts Predict 16% Gains Ahead For The Holdings of PBUS

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 46.82%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $2.93 per share when it actually produced earnings of $2.90, delivering a surprise of -1.02%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Bio-Rad, which belongs to the Zacks Medical - Products industry, posted revenues of $585.4 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.05%. This compares to year-ago revenues of $610.82 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Bio-Rad shares have lost about 25.7% since the beginning of the year versus the S&P 500's decline of -5.3%.
What's Next for Bio-Rad?
While Bio-Rad has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Bio-Rad: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.86 on $641.63 million in revenues for the coming quarter and $10.30 on $2.58 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, OrganiGram (OGI), has yet to report results for the quarter ended March 2025.
This cannabis producer is expected to post quarterly loss of $0.03 per share in its upcoming report, which represents a year-over-year change of +75%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
OrganiGram's revenues are expected to be $42.28 million, up 51.5% from the year-ago quarter.
Should You Invest in Bio-Rad Laboratories, Inc. (BIO)?
Before you invest in Bio-Rad Laboratories, Inc. (BIO), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
Organigram Global Inc. (OGI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates

Below is Validea's guru fundamental report for BIO RAD LABORATORIES INC (BIO). Of the 22 guru strategies we follow, BIO rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and P/E ratios, along with low debt and solid long-term earnings growth.
BIO RAD LABORATORIES INC (BIO) is a mid-cap value stock in the Scientific & Technical Instr. industry. The rating using this strategy is 71% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR:
FAIL
SALES:
PASS
CURRENT RATIO:
PASS
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS:
PASS
LONG-TERM EPS GROWTH:
FAIL
P/E RATIO:
PASS
PRICE/BOOK RATIO:
PASS
Detailed Analysis of BIO RAD LABORATORIES INC
BIO Guru Analysis
BIO Fundamental Analysis
More Information on Benjamin Graham
Benjamin Graham Portfolio
Top Benjamin Graham Stocks
About Benjamin Graham: The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976. Known as both the "Father of Value Investing" and the founder of the entire field of security analysis, Graham mentored several of history's greatest investors -- including Warren Buffett -- and inspired a slew of others, including John Templeton, Mario Gabelli, and another of Validea's gurus, John Neff. Graham built his fortune and reputation after living through some extremely difficult times, including both the Great Depression and his own family's financial woes following his father's death when Benjamin was a young man. His investment firm posted per annum returns of about 20 percent from 1936 to 1956, far outpacing the 12.2 percent average return for the market during that time.
Additional Research Links
Top NASDAQ 100 Stocks
Top Technology Stocks
Top Large-Cap Growth Stocks
High Momentum Stocks
Top Chip Stocks
High Insider Ownership Stocks
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

BIO Quantitative Stock Analysis - Benjamin Graham

Bio-Techne Corporation TECH recently opened a new Customer Experience Centre in Düsseldorf, Germany, to serve customers across the Europe, Middle East and Africa (“EMEA”) region. The facility's capacity should enable the company to grow its customer-centric team in the EMEA and support long-term regional growth.
More on TECH’s New Customer Experience Centre
The new Customer Experience Centre is scheduled to be opened in the first half of 2026. The facility will complement the company’s existing Demonstration Laboratory in the United Kingdom. Düsseldorf was chosen as the site for this new center due to its thriving life sciences sector and strategic proximity to the Benelux region, providing seamless access to customers from multiple European markets.
The facility will feature a state-of-the-art Demonstration Laboratory hosting Bio-Techne's full instrument portfolio, including the recently launched Leo System, powered by Simple Western Technology, which offers the throughput and precision of standard ELISAs in a fully automated western blot assay. It will also host the best-in-class spatial biology platform COMET, which is the only fully automated, high-throughput, hyperplex platform with superior tissue profiling capabilities.
Industry Prospects Favor Bio-Techne
Per a report by BioSpace, the life science market is projected to witness a compound annual growth rate (CAGR) of 10.28% from 2024 to 2033. This robust growth is driven by technological advancements, growing demand for personalized medicine, and increasing investments in research and development.
Other Developments by Bio-Techne
Earlier this month, Asuragen — a Bio-Techne brand — partnerd with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit. The research-use-only AmplideX Nanopore Carrier Plus Kit is a new genetic panel that will support software analysis for carrier screening research.
Last month, the company expanded its menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with advanced sensitivity and specificity, the Advanced Cell Diagnostics (“ACD”) branded RNAscope probe portfolio now covers more than 70,000 unique probes across over 450 species.
Latest Updates From Bio-Techne’s Peers
In the life sciences research space, Bio-Techne faces competition from some prominent MedTech players. These companies are also making notable developments in their respective businesses.
QIAGEN N.V. QGEN, one of Bio-techne's major competitors, recently announced a significant enhancement in the capabilities of its QIAcuity dPCR system, with a more than two-fold increase in the number of targets that can be simultaneously analyzed from a single biological sample. Additionally, QIAGEN partnered with Genomics England to support the delivery of the 100,000 Genomes Project, also known as the Generation Study. This first-of-its-kind initiative is aimed to sequence the genomes of 100,000 newborns in England, to screen over 200 selected conditions, enabling earlier diagnosis and treatment of rare conditions.
Another competitor of Bio-Techne is Thermo Fisher Scientific TMO. In January, the company’s Olink Explore Platform was selected by UK Biobank Pharma Proteomics Project (UKB-PPP) to support the world’s largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases.
Additionally, in 2024, the company introduced new additions to the Gibco CTS Detachable Dynabeads platform to further enhance the development and manufacturing of life-changing cell therapies.
Another competitor is Bio-Rad BIO, which made several advancements in 2024 to further expand the ddPCR platform into life science research and clinical diagnostics. For instance, the company invested in Geneoscopy to support the launch of its FDA-approved, non-invasive colorectal cancer screening test, powered by the ddPCR platform. According to the latest update, Bio-Rad’s QX600 Droplet Digital PCR (ddPCR) platform is currently robust and continues to grow.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
Bio-Techne Corp (TECH) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Bio-Techne Opens New Customer Experience Centre in Germany

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Monday, shares of Bio-Rad Laboratories Inc (Symbol: BIO) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $251.04 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 38.3. A bullish investor could look at BIO's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIO shares:
Looking at the chart above, BIO's low point in its 52 week range is $244 per share, with $387.99 as the 52 week high point — that compares with a last trade of $252.86.
Find out what 9 other oversold stocks you need to know about »
Also see:
ATXS YTD Return
Institutional Holders of USOY
GFOR shares outstanding history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	0.00 23.75
Price/Sales	2.66 3.01
P/B	0.99 2.20
P/FCF	18.99 18.30

Indicator	TTM Median
ROE	0.00 25.41
ROA	0.00 6.00
ROI	0.00 9.66
Net Worth	6.72 0.20
Quick Ratio	4.43 1.71
Current Ratio	5.99 2.83

Indicator	TTM Median
Net Profit Margin	0.00 10.25
Operating Margin	9.72 14.24
Gross Margin	53.50 68.57
Return on tangible equity	0.00 53.53

Indicator	TTM Median
EPS	2.54 0.37
EPS Forecast	1.73 0.37
Revenue	585.00M 16.00M
Gross Profit	306.00M —
EBITDA	24.00M —

Bio-Rad Laboratories, Inc.

Fundamental BIO

Valuation

Debts

Efficiency

Other ratios

Revenue